6879.TWO TCI GENE Inc.
- Market cap
- TWD 917M
- P/E
- 18.2x
- P/B
- 1.10x
- ROE
- 4.6%
- Dividend yield
- 5.77%
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2025.
Is 6879.TWO undervalued?
Graham number6879.TWO trades 5.6% below its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
TCI GENE Inc. fundamental analysis
No fundamental analysis for TCI GENE Inc. yet.
TCI GENE Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About TCI GENE Inc.
TCI GENE Inc., together with its subsidiaries, provides genetic testing and assessment services in Taiwan and Mainland China. It operates through Inspection and Consumable Products segments. The company offers memory, anti-aging, health management, child growth and development, nutritional metabolism and absorption, OB weight management, and SC skin management genetic testing; gut microbiota testing; and LDT cardiovascular drug gene testing services. It also provides precisi…
Full company profileTCI GENE Inc. financial statements
TCI GENE Inc. annual financial statements (TWD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 432M | 424M | 334M | 348M | 274M |
| Gross Profit | 239M | 243M | 175M | 204M | 153M |
| Operating Income | 114M | 91.1M | 6.02M | 55.8M | 19.1M |
| EBITDA | - | 121M | 25.9M | 81.9M | 52.3M |
| Net Income | 92.5M | 72.1M | 11.7M | 56.3M | 40.6M |
| EPS | 3.49 | 2.73 | 0.44 | 2.13 | 1.53 |
| Balance Sheet | |||||
| Total Assets | 560M | 1.16B | 1.17B | 1.10B | 1.01B |
| Total Liabilities | 169M | 143M | 156M | 101M | 98.6M |
| Shareholders' Equity | 380M | 1.01B | 987M | 975M | 891M |
| Cash & Short-term Investments | 326M | 933M | 696M | 98.4M | 251M |
| Cash Flow | |||||
| Operating Cash Flow | 119M | 110M | 17.8M | 57.0M | 151M |
| Capital Expenditure | 23.4M | 15.3M | 3.17M | 2.66M | 417K |
| Free Cash Flow | 95.8M | 95.1M | 14.7M | 54.3M | 151M |
| Ratios | |||||
| ROE | 24.3% | 7.2% | 1.2% | 5.8% | 4.6% |
| ROA | 16.5% | 6.2% | 1.0% | 5.1% | 4.0% |
| Net Profit Margin | 21.4% | 17.0% | 3.5% | 16.2% | 14.8% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
TCI GENE Inc. dividends
- Dividend yield
- 5.77%
- Forward dividend
- -
- Payout ratio
- 130.4%
- Ex-dividend date
- Sep 5, 2025
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | TWD 52.9M | 2.00 | 130.4% |
| 2024 | TWD 26.5M | 1.00 | 47.0% |
| 2023 | TWD 52.9M | 2.00 | 453.3% |
| 2022 | TWD 53.6M | 2.03 | 74.4% |
| 2021 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns TCI GENE Inc.
Ownership data of TCI GENE Inc. is not available yet.
TCI GENE Inc. company profile
- Company name
- TCI GENE Inc.
- Ticker
- 6879.TWO
- ISIN
- TW0006879000
- Exchange
- Taiwan OTC Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Fiscal year end
- December
- Address
- No. 185, Gangqian Road, Taipei, Taiwan, 11494
- Phone
- 886 2 2658 1218
- Website
- tci-gene.com
About TCI GENE Inc.
TCI GENE Inc., together with its subsidiaries, provides genetic testing and assessment services in Taiwan and Mainland China. It operates through Inspection and Consumable Products segments. The company offers memory, anti-aging, health management, child growth and development, nutritional metabolism and absorption, OB weight management, and SC skin management genetic testing; gut microbiota testing; and LDT cardiovascular drug gene testing services. It also provides precision prediction and personalized health management plans; and adipose-derived mesenchymal stem cells, natural killer immune cells, and immune cell storage programs. In addition, the company manufactures and sells testing reagents, health food, and beauty products; and health and nutritional supplements. TCI GENE Inc. was founded in 2011 and is based in Taipei, Taiwan.